BioSpace News Archive

Atara Biotherapeutics, Inc. announced new magnetic resonance imaging biomarker and open-label extension clinical data from the study of ATA188, an investigational Epstein-Barr virus -targeted T-cell immunotherapy, in progressive multiple sclerosis.

Orexo AB, welcomes Edward Kim, M.D., as new Chief Medical Officer.

Scorpion Therapeutics, Inc. announced preclinical proof-of-concept data for STX-721, the Company’s first development candidate from its STX-EGFR-EXON-20 program. STX-721 is a next-generation, orally delivered therapy, designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors, a well-known, clinically validated oncogenic driver in non-small cell lung cancer.

Ryvu Therapeutics announced updated clinical data on RVU120 in relapsed/refractory metastatic or advanced solid tumors, preclinical data on RVU120 enhancing antibody-dependent cell-mediated cytotoxicity and discovery, and optimization data on novel MTA-cooperative PRMT5 inhibitors at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place on October 26 - 28 in Barcelona, Spain.

Mogling Bio, a privately held biotech company, announces that it has successfully completed its first seed investment round.

Biogen Inc. announced new data on multiple sclerosis disease measurement and advanced analytics being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis meeting October 26-28, 2022.

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022.

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the third quarter ended October 1, 2022.

Nuvalent, Inc. announced the presentation of new preclinical data for NVL-330, its recently nominated HER2-selective inhibitor, and NVL-655, its ALK-selective inhibitor currently under investigation in the ALKOVE-1 Phase 1/2 study for advanced ALK-positive non-small cell lung cancer and other solid tumors.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today will present new data across its protein degradation platform at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit.